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Abstract
Background: Insects detect attractive and aversive chemicals using several families of chemosensory receptors, including
the OR family of olfactory receptors, making these receptors appealing targets for the control of insects. Insect ORs are
odorant-gated ion channels, comprised of at least one common subunit (the odorant receptor co-receptor subunit, Orco)
and at least one variable odorant specificity subunit. Each of the many ORs of an insect species is activated or inhibited by
an unique set of odorants that interact with the variable odorant specificity subunits, making the development of OR
directed insect control agents complex and laborious. However, several N-,2-substituted triazolothioacetamide compounds
(VUAA1, VU0450667 and VU0183254) were recently shown to act directly on the highly conserved Orco subunit, suggesting
that broadly active compounds can be developed. We have explored the chemical space around the VUAA1 structure in
order to identify new Orco ligands.
Principal Findings: We screened ORs from several insect species, using heterologous expression in Xenopus oocytes and an
electrophysiological assay, with a panel of 22 compounds structurally related to VUAA1. By varying the nitrogen position in
the pyridine ring and altering the moieties decorating the phenyl ring, we identified two new agonists and a series of
competitive antagonists. Screening smaller compounds, similar to portions of the VUAA1 structure, also yielded competitive
antagonists. Importantly, we show that Orco antagonists inhibit odorant activation of ORs from several insect species.
Detailed examination of one antagonist demonstrated inhibition to be through a non-competitive mechanism.
Conclusions: A similar pattern of agonist and antagonist sensitivity displayed by Orco subunits from different species
suggests a highly conserved binding site structure. The susceptibility to inhibition of odorant activation by Orco antagonism
is conserved across disparate insect species, suggesing the ligand binding site on Orco as a promising target for the
development of novel, broadly active insect repellants.
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Introduction
Olfaction drives many insect behaviors, including those
deleterious to human health. Insects detect attractive and aversive
chemicals using several families of chemosensory receptors,
including the OR family of insect olfactory receptors [1,2,3].
These receptors, located on the dendrites of olfactory sensory
neurons (OSNs), are appealing targets for the control of insects
involved in disease propagation and agricultural damage. In
contrast to mammalian ORs, which are a large family of G-
protein coupled receptors, the insect ORs are a novel class of
ligand (odorant) gated, non-selective cation ion channels [4,5].
Insect ORs are multimeric complexes of unknown stoichiometry,
formed by a common subunit (the odorant receptor co-receptor
subunit known as Orco [6]) that is highly conserved across
different species and a variable subunit that confers odorant
specificity [3,7,8,9,10,11,12,13]. These receptors have generally
been thought to function as obligate heteromultimers [3], with
only a few reports of homomeric function [5,14,15]. Within an
individual OR, both Orco and the specificity subunit may make
contributions to the structure and properties of the ion pore
[16,17,18]. The specificity subunits are thought to mediate
odorant recognition, because changing this subunit can alter
odorant preference [19,20,21,22] and mutations in a specificity
subunit can alter odorant sensitivity [23,24]. Because Orco is
common to every insect OR, the great diversity in odorant
preference among the ORs of each insect species is generated by
the specificity subunits [3].
The novel structure of insect ORs and lack of similar receptors
in humans and other mammals [7] suggests that improved control
of destructive insect species can be achieved through the
development of new, OR directed compounds with higher
selectivity and lower environmental toxicity than currently
available insecticides and repellants. One approach to developing
these compounds involves the identification of particular specificity
subunits that mediate recognition of behaviorally specific odorants
[19,22,25,26,27], followed by extensive ligand screening [28]. A
drawback of this approach is that high diversity among the
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which odorants and specificity subunits are key to species specific
behaviors [29] means that receptor identification, extensive
screening and ligand optimization would be required for each of
the many potential target receptors. Compounds that are active at
multiple ORs of many different species would be of much greater
utility. The identification of VUAA1 [28] as a novel agonist and
VU0183254 as a novel antagonist of insect ORs [30], each acting
at a binding site on the Orco subunit from several insect species,
suggests that such generally active compounds can be developed.
In this study, we expand the repertoire of Orco agonists and
antagonists. We screen ORs from several insect species, using
heterologous expression in Xenopus oocytes and electrophysiolog-
ical recording, with a panel of compounds structurally related to
VUAA1. We identify two new Orco agonists, as well as a series of
competitive antagonists of the Orco subunit. A similar pattern of
agonist and antagonist sensitivity displayed by Orco subunits from
a variety of different species suggests that the binding site on Orco
has a highly conserved structure. We also show that the Orco
antagonists can inhibit odorant activation of insect ORs through a
non-competitive mechanism. Susceptibility to inhibition of odor-
ant activation through Orco antagonism is conserved across
disparate insect species, suggesting Orco pharmacology as a
promising area for the development of novel, broadly active insect
repellants.
Results
In Figure 1A, we expressed ORs from several insect species in
Xenopus oocytes and assayed receptor function by two-electrode
voltage clamp electrophysiology: Cqui\Orco+Cqui\Or10, an OR
from the Southern House Mosquito (Culex quinquefasciatus) that
responds to oviposition attractants, such as 3-methylindole [25];
Dmel\Orco+Dmel\Or35a, an OR from Drosophila melanogaster that
responds to a variety of aliphatic alcohols, aldehydes and esters
[16,20]; Onub\Orco+Onub\Or1, an OR from the European
Corn Borer (Ostrinia nubilalis) that responds to mating pheromones,
such as E12–14:OAc [31]. Similar to the previous report [28], we
found that VUAA1 (100 mM) could activate each of these ORs.
Also as reported previously [28], we found that Orco could form a
functional channel when expressed in the absence of specificity
subunits. We observed current responses when VUAA1 was
applied to oocytes expressing either Dmel\Orco or Cqui\Orco,
but no specificity subunits (Fig. 1A). We did not observe functional
expression of Onub\Orco channels, but whether this is due to a
failure of expression or a failure of function is not known. No
responses to VUAA1 were observed with sham (water) injected
oocytes (Fig. S1).
We sought to identify additional agonists of the Orco subunit by
screening a panel of 22 compounds (termed Orco Ligand
Candidates, OLCs). Fourteen compounds (OLC2–OLC15) were
structurally related to the full VUAA1 structure (Fig. S2), with
alterations to the pyridine ring (OLC2–OLC4) and a variety of
substitutions on the phenyl ring (OLC5 -OLC15). Eight
compounds (OLC16–OLC22) were similar to portions of the
VUAA1 structure (Fig. S3). All 22 OLCs were screened at a
concentration of 100 mM against oocytes expressing Dmel\Or-
co+Dmel\Or35a, Dmel\Orco alone, Cqui\Orco+Cqui\Or10 or
Cqui\Orco alone, and a subset (OLC2–9, OLC12) was screened
against oocytes expressing Onub\Orco+Onub\Or1 (Fig. 1B,C,
Table S1). While most of these compounds displayed little or no
agonist activity, the screen identified two new agonists of the Orco
subunit (Fig. 1D). OLC3, with the pyridine nitrogen moved from
the 3 position (as in VUAA1) to the 4 position, was effective in
activating each of the 3 receptor complexes, as well as the
homomeric channels formed by Dmel\Orco and Cqui\Orco.
OLC12, with the nitrogen in the 4 position of the pyridine ring
and the 4-ethyl moiety on the phenyl ring (as in VUAA1) changed
to a 4-isopropyl moiety, was more effective than either VUAA1 or
OLC3 in activating the 3 receptor complexes and the homomeric
channels formed by Dmel\Orco and Cqui\Orco. No responses to
OLC3 or OLC12 were observed with sham (water) injected
oocytes (Fig. S1). We explored the activity of these agonists in
more detail by constructing concentration-response curves for
activation of Dmel\Orco+Dmel\Or35a (Fig. 2A) and Dmel\Orco
alone (Fig. 2B). OLC12 was significantly more potent than
VUAA1 and OLC3 in both the heteromeric and homomeric
contexts (Table 1). OLC 12 also displayed a significantly greater
maximal response in the Dmel\Orco+Dmel\Or35a context
(Fig. 2A), while OLC3 appeared to yield a greater maximal
response in the Dmel\Orco context (Fig. 2B). However, we were
unable to obtain saturation for OLC3 (or VUAA1) activation of
Dmel\Orco alone, because these compounds were not fully
soluble at higher concentrations.
We next screened the panel for antagonist activity. OLC12 was
used to activate Dmel\Orco+Dmel\Or35a (10 mM OLC12, the
EC25) or Dmel\Orco (30 mM OLC12, the EC39) and 100 mMo f
each compound (the 20 remaining compounds after OLC3 and
OLC12 were excluded) was tested for the ability to inhibit the
OLC12 response (Fig. 3). While many of these compounds showed
some antagonist activity, we chose to concentrate on six
compounds that displayed substantial inhibition of agonist
activation of both Dmel\Orco+Dmel\Or35a and Dmel\Orco
alone (Fig. 3E): OLC2, with the pyridine nitrogen shifted to the 2
position; OLC9, with a 4-butyl moiety on the phenyl ring;
OLC15, with both the pyridine nitrogen in the 2 position and a 4-
butyl moiety on the phenyl ring; OLC14, with the pyridine
nitrogen at the 4 position and a dimethylamino moiety on the
phenyl ring; OLC20, with a structure similar to a portion of the
OLC2; OLC22, similar to a portion of the OLC9 structure. We
examined the activity of these compounds in more detail by
constructing concentration-inhibition curves for Dmel\Orco+D-
mel\Or35a and Dmel\Orco alone (Fig. 4A–B, Table 1). These
compounds displayed similar potencies for inhibition of OLC12
activation, with IC50’s ranging from 15 mMt o8 1 mM. It is
important to note that while the IC50 values for antagonism by
these compounds may be directly compared within one receptor
context (Dmel\Orco+Dmel\Or35a or Dmel\Orco alone), caution
should be exercised when comparing values for Dmel\Orco+D-
mel\Or35a with those for Dmel\Orco alone. The agonist
(OLC12) concentrations used in each case were of similar potency
(EC25 and EC39, respectively), but were not precisely equipotent.
When these six compounds, as well as OLC8 and OLC16, were
tested against Cqui\Orco+Cqui\Or10 and Cqui\Orco (Fig. S4),
the observed pattern of antagonist activity was similar to what we
observed for Dmel\Orco+Dmel\Or35a and Dmel\Orco.
The antagonists that we have identified have structural
similarity to VUAA1, OLC3 and OLC12, suggesting that they
may compete for occupation of the same site on the Orco subunit.
To determine whether this is the case, we compared the extent of
blockade of Dmel\Orco+Dmel\Or35a that could be achieved by
100 mM of each of six antagonists (OLC2, OLC9, OLC14,
OLC15, OLC20 and OLC22) when the agonist (OLC12)
concentration was increased from 10 mM (as in Fig. 3C) to
100mM (Fig. 4C). In each case, the antagonist was significantly less
effective at inhibiting the response to the higher concentration of
agonist, indicating a competitive interaction. We examined this
issue in more detail for OLC15 antagonism of OLC12 activation
Insect Orco Subunit Pharmacology
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analysis of OLC15 inhibition of activation by 10 mM OLC12
yielded an IC50 of 1561 mM. When the concentration of OLC12
was increased to 100 mM, the concentration-inhibition curve was
significantly shifted to the right (IC50=6767 mM, p,0.0001, F
test), again indicating a competitive interaction.
The identification of compounds, such as OLC15, that
competitively antagonize the activation of Orco by agonists such
as OLC3 and OLC12 is interesting. However, our current lack of
knowledge about a physiological role for Orco agonism makes the
utility of antagonizing of this process questionable. Thus, we
wondered whether these Orco antagonists could also interfere with
odorant activation. A recent publication [30] identified
VU0183254 as an Orco antagonist capable of allosterically
inhibiting odorant activation of ORs from A. gambiae. We tested
whether a similar effect could be exerted by OLC2, OLC15 and
OLC20 on the response of Dmel\Orco+Dmel\Or35a to hexanol.
While OLC2 (100 mM) did not inhibit the hexanol response, co-
application of OLC15 (50 mM) or OLC20 (200 mM) resulted in
substantial inhibition (Fig. 5A,B). We then tested OLC2 and
OLC15 against ORs from several additional species (Fig. 5B).
Both compounds inhibited activation of Cqui\Orco+Cqui\Or10
by 3-methylindole, activation of Agam\Orco+Agam\Or65 by
eugenol and activation of Onub\Orco+Onub\Or1 by E12–
14:OAc. The C. quinquefasciatus and O. nubilalis ORs were
significantly more sensitive to inhibition by OLC15 than OLC2
(p,0.01, t-test), while the A. gambiae OR was equally sensitive to
both compounds. Thus, while there was variation in sensitivity,
odorant activation of each OR could be inhibited through Orco
antagonism.
To further understand the mechanism of inhibition of odorant
activation by Orco antagonism, we examined the effect of OLC15
on Cqui\Orco+Cqui\Or10 in more detail. Concentration-inhibi-
tion curves for OLC15 were generated at two different concen-
Figure 1. Identification of OLC3 and OLC12 as Orco agonists. A) VUAA1 activates both heteromeric (top traces) and homomeric (bottom
traces) insect ORs expressed in Xenopus oocytes and assayed by two electrode voltage clamp electrophysiology. Compounds were applied for 60 sec
with a 9 min wash between applications. VUAA1 was applied at 100 mM. Oocytes expressing Cqui\Orco + Cqui\Or10 or Cqui\Orco were also exposed
to 30 nM 3-methylindole (3-MI). Oocytes expressing Dmel\Orco + Dmel\Or35a or Dmel\Orco were also exposed to 3 mM Hexanol (HEX). Oocytes
expressing Onub\Orco + Onub\Or1 or Onub\Orco were also exposed to 1 mM E12–14:OAc (E12). B) OLC3 activates both heteromeric and homomeric
insect ORs. Oocytes expressing Dmel\Orco + Dmel\Or35a (top trace) or Dmel\Orco (bottom trace) were challenged with 60 sec applications of
100 mM OLC2, OLC3, OLC4, OLC5 and VUAA1, with 9 min washes between applications. C) Results from a screen of 22 compounds (each applied at
100 mM) for Orco agonist activity. Responses are normalized to the response of the same oocyte to 100 mM OLC3 and presented as the mean of 3–8
oocytes (SEM values may be found in Table S1). D) Structures of VUAA1, OLC3 and OLC12.
doi:10.1371/journal.pone.0036784.g001
Insect Orco Subunit Pharmacology
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36784trations of 3-methylindole. The EC50 for activation of Cqui\Or-
co+Cqui\Or10 by 3-methylindole is 90617 nM [25]. The IC50
values for OLC15 inhibition of receptor activation by 10 nM 3-
methylindole (EC10) and 100 nM 3-methylindole (EC53) were not
significantly different (Fig. 5C), suggesting a non-competitive
mechanism for OLC15 inhibition of odorant activation. This
contrasts with the competitive mechanism for OLC15 inhibition of
direct Orco activation by OLC12 that we demonstrated with a
Drosophila receptor (Fig. 4C,D). Comparison of the concentration-
response relationship for 3-methylindole activation of Cqui\Or-
co+Cqui\Or10 in the absence and presence of OLC15 showed
that while the maximal response was significantly reduced by the
presence of OLC15, the EC50 for activation was unchanged
(Fig. 5D). This result provides further support for a non-
competitive mechanism for inhibition of odorant activation by
Orco antagonists.
Discussion
The recent identification of VUAA1 as an activator of insect
ORs through direct Orco agonism [28] and a subsequent report
identifying VU0183254 as an Orco antagonist [30], have revealed
the existence of a ligand-binding site on the Orco subunit. We
have expanded on these findings by identifying two additional
Orco agonists, as well as a larger series of Orco antagonists. With
this expanded panel of agonists and antagonists, we compared the
pharmacological properties of Orco subunits from several different
species. We found a similar pattern of activation and inhibition by
these compounds among Orco subunits of disparate insect species.
This result suggests that the ligand-binding site on Orco is
structurally conserved, consistent with the high level of protein
sequence identity among Orco subunits of different species [8,9].
The in vivo function of this site, in any, is currently unknown.
While much additional work will be required, our results,
together with the recent reports from Zwiebel and colleagues
[28,30], allow an initial discussion of the structural requirements
for agonism and antagonism of the Orco subunit of insect ORs.
The requirements for agonist activity appear to be quite strict,
with only minor changes being tolerated. Movement of the
pyridine nitrogen from the 3 position to the 4 position and
addition of a methyl to create an isopropyl group on the phenyl
ring both yield compounds with agonist activity (OLC3 and
OLC12). The three compounds with substantial agonist activity
(VUAA1, OLC3 and OLC12) vary in both potency (EC50) and
efficacy (maximal response). In a whole receptor context
(Dmel\Orco+Dmel\Or35a), OLC12 displays greater efficacy
Figure 2. OLC12 is a more potent Orco agonist than VUAA1 or
OLC3. Concentration-response analysis for VUAA1, OLC3 and OLC12
activation of Dmel\Orco + Dmel\Or35a (A) and Dmel\Orco (B). Each
response was normalized to the response of the same oocyte to 30 mM
OLC3. EC50 values can be found in Supplementary Table 2.
doi:10.1371/journal.pone.0036784.g002
Table 1. EC50 and IC50 values for agonists and antagonists of Dmel\Orco.
Compound EC50 (mM) IC50 (mM)
Dmel\Orco + Dmel\Or35a Dmel\Orco
Dmel\Orco + Dmel\Or35a (activated by
10 mM OLC12)
Dmel\Orco (activated by 30 mM
OLC12)
VUAA1 57±13 190630
OLC3 56683 4 6 6126
OLC12 1863***
{ 3563***
{{{
OLC2 24652 3 63
OLC9 40696 9 67
OLC14 81623 2564
OLC15 15611 5 62
OLC20 55615 57619
OLC22 26645 2 618
Statistical differences from OLC3:
***p,0.001. Statistical differences from VUAA1:
{p,0.05;
{{{p,0.001.
doi:10.1371/journal.pone.0036784.t001
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partial agonists. However, in an Orco alone context (Dmel\Orco),
OLC3 appears to have the greater efficacy (although solubility
issues prevent us from achieving saturation), with OLC12 and
VUAA1 being partial agonists.
All other modifications to the VUAA1 lead structure yielded
compounds that were, with a few exceptions (OLC10 and
OLC11), devoid of agonist activity. The very low level of agonist
activity observed with OLC10, with the ethyl group on the phenyl
ring changed to a bromo group, is converted to competitive
antagonism with the addition of a methyl group at the 2 position of
the phenyl ring to yield VU0450667 [30]. While most of the
compounds tested lack agonist activity, many displayed antagonist
activity. Minor modifications, such as the shift of the pyridine
nitrogen to the 2 position (OLC2) or conversion of the 4-
ethylphenyl group to a 3,4-dimethylphenyl group (OLC13),
eliminated agonist activity and generated antagonists. Larger
modifications to the phenyl group, such as conversion to a 4-
butylphenyl group (OLC15) or a 4-dimethylaminophenyl group
(OLC14), also produced antagonists. VU0183254, a related
structure with a furanotriazole core and a phenothiazine
substituting for the 4-ethylphenyl group, also functions as an
antagonist [30]. The antagonist activity of VU0183254 [30], as
well as the smaller structures we have identified (OLC20 and
OLC22), suggests that the chemical space containing viable Orco
antagonists may be relatively broad and that further exploration is
merited.
The observation that Orco subunits can form functional
channels in the absence of specificity subunits ([5,28,30] and this
study) suggests that both heteromeric and homomeric channel
complexes may exist in oocytes when we express a specificity
subunit and an Orco subunit. This may raise concerns about
whether Orco ligands can act on heteromeric complexes. The
three agonists (VUAA1, OLC3 and OLC12) and six antagonists
(OLC2, OLC9, OLC14, OLC15, OLC20 and OLC22) we
examined in detail were not significantly more potent when
applied to oocytes expressing both Dmel\Or35a and Dmel\Orco
than when applied to oocytes expressing Dmel\Orco alone
(Table 1). However, Orco agonists (VUAA1, OLC3 and
OLC12) and antagonists (OLC2 and OLC15) clearly interact
with a heteromeric Onub\Orco+Onub\Or1 (Figs. 1 and 5),
because homomeric Onub\Orco is non-functional (Fig. 1).
Further, the Orco antagonists we have identified were capable
of inhibiting odorant activation of heteromeric ORs (Fig. 5).
Similar results were reported for the antagonist VU0183254 [30].
These findings indicate that the binding site of the Orco subunit is
functional when Orco is part of a heteromeric OR complex.
Interestingly, Orco antagonists vary in their ability to alloste-
rically inhibit activation of ORs by odorant. OLC2 and OLC15
display similar potencies for inhibition of direct Orco activation by
an Orco agonist such as OLC12 (Fig. 4A,B). However, while
OLC15 can also inhibit odorant activation of the Drosophila
receptor, OLC2 could not (Fig. 5B). It is possible that OLC2
inhibition of odorant activation of this receptor may become
apparent at higher concentrations, but the poor solubility of
OLC2 at concentrations above 100 mM renders this problematic.
A differential ability of Orco antagonists to inhibit odorant
activation was also observed with ORs from A. gambiae [30]. Thus,
relative potencies for inhibition of direct Orco activation (by an
Orco agonist) may not be good predictors of the ability of a
Figure 3. Identification of new Orco antagonists. A) Co-application of 100 mM OLC2 inhibits activation of Dmel\Orco by 30 mM OLC12. B) Co-
application of 100 mM OLC8 fails to block activation of Dmel\Orco by 30 mM OLC12. C–D) Results of a screen of 20 compounds for Orco antagonism.
Responses of Dmel\Orco + Dmel\Or35a to 10 mM OLC12 (EC25)( C) or of Dmel\Orco to 30 mM OLC12 (EC39)( D) in the presence of 100 mM of each
candidate antagonist are presented as a percentage of the average of the two preceding responses to OLC12 alone (mean6SEM, n=326). Sh, sham.
E) Structures of Orco antagonists.
doi:10.1371/journal.pone.0036784.g003
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odorant.
The presence of a conserved binding site through which ORs
from many different insect species may be activated or inhibited
obviates the need for the laborious development of compounds
directed toward particular ORs of individual species. By targeting
Orco, the development of compounds with simultaneous utility
against many insect species may be possible. Indeed, in our study
and the previous reports [28,30], Orco agonism and antagonism
was observed with ORs of insect species from several different
orders, including Diptera (D. melanogaster, A. gambiae, C. quinque-
fasciatus), Lepidoptera (O. nubilalis, H. virescens) and Hymenoptera
(H. saltator). An OR from A. aegypti has also been shown to respond
to VUAA1 and OLC3 [32]. This conservation of susceptibility to
Orco agonism and antagonism identifies Orco as a promising
target for the development of novel, broadly active insect
repellants. Importantly, the ability of an Orco agonist to activate
OSNs, as well as the ability of an antagonist to inhibit odorant-
evoked OSN responses, have has been demonstrated in vivo using
single sensillum recordings in A. gambiae [28,30]. Unfortunately,
the currently identified Orco agonists and antagonists, such as
OLC12 and OLC15 (this study), or VUAA1 [28] and VU0183254
[30], are unlikely to be useful as insect repellants due to low
volatility. However, we have also shown that smaller structures,
such as OLC20, are able to interact with Orco to inhibit activation
of an OR complex by odorant. Thus, the pursuit of small, volatile
agonists and antagonists of the Orco subunit may be a productive
new phase of insect repellant development.
Materials and Methods
Materials
Xenopus laevis frogs were purchased from Nasco. The care and
use of X. laevis frogs in this study were approved by the University
of Miami Animal Research Committee and meet the guidelines of
the National Institutes of Health. Odorants, Orco ligands and
other chemicals were from Sigma-Aldrich, except for VUAA1,
which was purchased from Vitas-M Laboratory, Ltd. (Apeldoorn,
Netherlands) through eMolecules, Inc. (Solana Beach, CA).
Dmel\Or35a and Dmel\Orco were generously provided by J.
Carlson and L. Vosshall, respectively. Agam\Or65 and Aga-
m\Orco, in pSP64T-Oligo and pT7TS, respectively [22], were
generously provided by L. Zwiebel. Onub\Or1 and Onub\Orco
were previously cloned [31], as were Cqui\Or10 and Cqui\Orco
[25,26]. Dmel\Or35a, Dmel\Orco, Onub\Or1, Onub\Orco,
Cqui\Or10 and Cqui\Orco were subcloned into pGEMHE [33].
Figure 4. Competitive antagonism of Orco activation. A-B) Concentration-inhibition analysis for OLC2, OLC9, OLC14, OLC15, OLC20 and
OLC22 inhibition of Dmel\Orco + Dmel\Or35a activated by 10 mM OLC12 (EC25)( A) and Dmel\Orco activated by 30 mM OLC12 (EC39)( B). IC50 values
may be found in Table 1. C) Increasing the concentration of agonist (OLC12) decreases the effectiveness of Orco antagonists. 100 mM OLC2, OLC9,
OLC14, OLC15, OLC20, or OLC22 was co-applied with 10 mM OLC12 or 100 mM OLC12 to oocytes expressing Dmel\Orco + Dmel\Or35a. Responses in
the presence antagonist are presented as a percentage of the average of the two preceding responses to OLC12 alone (mean6SEM, n=325).
Statistical significance (t-test): *p,0.05; **p,0.01; ***p,0.001. D, Altering agonist (OLC12) concentration, shifts the OLC15 inhibition curve. The IC50
values for OLC15 inhibition of 10 mM OLC12 (1561 mM) and 100 mM OLC12 (6767 mM) are significantly different (p,0.0001, F test).
doi:10.1371/journal.pone.0036784.g004
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Oocytes were surgically removed from mature Xenopus laevis
frogs. Follicle cells were removed by treatment with Collagenase B
(Boehringer Mannhem) for 2 hours at room temperature. Capped
cRNA encoding each DmOR subunit was generated using
mMessage mMachine kits (Ambion). For heteromeric ORs,
25 ng of cRNA encoding each OR subunit was injected into
Stage V-VI Xenopus oocytes. For expression of Orco alone, 50 ng
of cRNA was injected. Oocytes were incubated at 18uC in Barth’s
saline (in mM: 88 NaCl, 1 KCl, 2.4 NaHCO3, 0.3 CaNO3,
0.41 CaCl2, 0.82 MgSO4, 15 HEPES, pH 7.6, and 150 mg/ml
ceftazidime) for 2–5 days prior to electrophysiological recording.
Electrophysiology and Data Capture
Odorant and Orco ligand induced currents were recorded under
two-electrode voltage clamp in Xenopus laevis oocytes expressing
ORs, using an automated parallel electrophysiology system
(OpusExpress 6000A; Molecular Devices). Oocytes were perfused
withND96(inmM:96 NaCl,2 KCl,1 CaCl2,1 MgCl2,5HEPES,
pH 7.5).Odorantstocksolutions(0.5or1 M)andOrcoligandstock
solutions (100 mM) were prepared in DMSO and diluted in ND96.
Unlessotherwisenoted,applicationswerefor60 secataflowrateof
1.0 ml/min, with extensive washing in ND96 (9 or 20 min at
4.6 ml/min) between applications. Micropipettes were filled with
3 M KCl and had resistances of 0.222.0 MV. The holding
Figure 5. Non-competitive inhibition of odorant activation of insect ORs by an Orco antagonist. A) Oocytes expressing Dmel\Orco +
Dmel\Or35a were exposed to 60 sec applications of 3 mM hexanol (HEX), with 20 min washes between applications. OLC2, OLC15 or OLC20 (100 mM)
were applied for 90 sec preceding the second application of HEX and then co-applied during the HEX application. Top trace, OLC2 fails to inhibit HEX
activation of Dmel\Orco + Dmel\Or35a. Middle trace, OLC15 inhibits HEX activation of Dmel\Orco + Dmel\Or35a. Bottom trace, OLC20 inhibits HEX
activation of Dmel\Orco + Dmel\Or35a. B) OLC compounds inhibit odorant activation of ORs from a variety of insect species. Oocytes expressing
Cqui\Orco+Cqui\Or10 were activated by 100 nM 3-methylindole (3-MI), oocytes expressing Dmel\Orco + Dmel\Or35a were activated by 3 mM HEX,
oocytes expressing Agam\Orco + Agam\Or65 were activated by 100 nM eugenol (Eug) and oocytes expressing Onub\Orco + Onub\Or1 were
activated E12–14:OAc (E12). Current responses in the presence of OLC compounds (100 mM) were compared to the preceding response to odorant
alone and are presented as mean6SEM (n=3214). C) Altering odorant concentration fails to alter the inhibition curve for OLC15 antagonism of
Cqui/Orco + Cqui\Or10 activation by 3-MI. The IC50 values for OLC15 inhibition of responses to 10 nM 3-MI (1.560.2 mM) and 100 nM 3-MI
(2.060.3 mM) do not differ (p=0.13, F test). D) Co-application of 3 mM OLC15 significantly reduces the maximal response to 3-MI, but does not alter
the EC50 for 3-MI activation. The maximal response to 3-MI in the presence of 3 mM OLC15 was significantly lower (6262%) than the maximal
response in the absence of OLC15 (p,0.05, F test). The EC50 for 3-MI activation of Cqui\Orco + Cqui\Or10 was 3136103 nM, while the EC50 in
presence of 3 mM OLC15 was 275641 nM (p=0.81, F test).
doi:10.1371/journal.pone.0036784.g005
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low pass) at 20 Hz (23 db) and sampled at 100 Hz, were captured
and stored using OpusXpress 1.1 software (Molecular Devices).
Experimental Protocols and Data Analysis
In inhibition assays, oocytes were exposed to 60 sec applications
of OLC12 with 9 min washes between applications (Fig. 3 and 4) or
60 sec applications of odorant with 20 min washes between
applications (Fig. 5). Oocytes were then exposed to a 90 sec
application of antagonist candidate, immediately followed by a
60 sec co-application of antagonist candidate and OLC12 or
odorant. Oocytes were then exposed to a final 60 sec application of
OLC12 or odorant. Example traces illustrating this protocol are
shown in Fig. 3A,B and 5A. The current response in the presence of
antagonist candidate was compared to the preceding response(s) to
OLC12 (or odorant) alone.
Initial analysis of electrophysiological data was done using
Clampfit 9.1 software (Molecular Devices). Curve fitting and
statistical analyses were done using Prism 5 (Graphpad). Concen-
tration-response data were fit to the equation: I=Imax/(1+(EC50/
X)
n) where I represents the current response at a given
concentration of odorant, X; Imax is the maximal response; EC50
is the concentration of agonist yielding a half maximal response; n
is the apparent Hill coefficient. Concentration-inhibition data
were fit to the equation: I=Imax/(1+(X/IC50)
n) where I represents
the current response at a given concentration of inhibitor, X; Imax
is the maximal response in the absence of inhibitor; IC50 is the
concentration of inhibitor present that still allows a half maximal
response from odorant; n is the apparent Hill coefficient. Statistical
significance was assessed using a two-tailed unpaired t test, an F
test, or a one-way analysis of variance followed by the Bonferroni’s
post-test, as appropriate.
Supporting Information
Figure S1 Sham (water injected) oocytes do not respond
to Orco agonists and antagonists. Compounds were applied
for 60 seconds at a concentration of 100 mM, except for OLC15
which was applied at 50 mM. Each trace is representative of results
from 4 oocytes.
(PDF)
Figure S2 N-,2-substituted triazolothioacetamide com-
pounds tested in this study.
(PDF)
Figure S3 Additional structures tested in this study.
(PDF)
Figure S4 Antagonism of Cqui\Orco. Results of a screen of
8 compounds for Orco antagonism. Responses of Cqui\Orco +
Cqui\Or10 to 3 mM OLC12 (,EC25) (A) or of Cqui\Orco to
30 mM OLC12 (,EC10) (B) in the presence of each candidate
antagonist are presented as a percentage of the average of the two
preceding responses to OLC12 alone (mean6SEM, n=325).
(PDF)
Table S1 Values from Figure 1C. Response amplitudes to
100 mM of each compound are presented as a percentage of the
response of the same oocyte to 100 mM OLC3 (mean6SEM,
n=328). nt, not tested.
(PDF)
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